What the FDA labels say about taking them together
Cyclophosphamide and daratumumab/hyaluronidase
Daratumumab/hyaluronidase's FDA label of September 3, 2026 names cyclophosphamide in its warnings and precautions section; the cyclophosphamide labels PlainMeds reads (4) do not name daratumumab/hyaluronidase. The daratumumab/hyaluronidase label: “… amyloidosis who received DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone.”
Check it at the source: the cyclophosphamide FDA label on DailyMed (effective January 19, 2026, Amneal Pharmaceuticals LLC); the daratumumab/hyaluronidase FDA label on DailyMed (effective September 3, 2026).
What does the cyclophosphamide label say about daratumumab/hyaluronidase?
Cyclophosphamide's label (effective January 19, 2026) and its 3 other brand-application labels do not name daratumumab/hyaluronidase in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Cyclophosphamide), Amneal Pharmaceuticals LLC, effective January 19, 2026 (SPL set 520bfe39-dfd5-4a20-9a37-80078afded0d), via openFDA; the full label on DailyMed
What does the daratumumab/hyaluronidase label say about cyclophosphamide?
Daratumumab/hyaluronidase label, warnings and precautionsToxicity in Patients with Light Chain (AL) Amyloidosis Serious or fatal cardiac adverse reactions occurred in patients with light chain (AL) amyloidosis who received DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone [see Adverse Reactions (6.1) ].
Source: FDA drug label (Darzalex Faspro), Janssen Biotech, Inc., effective September 3, 2026 (SPL set 4bb241af-4299-4373-8762-2d6709515db0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclophosphamide | Daratumumab/hyaluronidase | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Leukemia, lymphoma and myeloma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.67 per capsule 50 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once